The Clinical Significance of CRNDE Gene Methylation, Polymorphisms, and CRNDEP Micropeptide Expression in Ovarian Tumors
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147531 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Laura Aleksandra Szafron und 6 weiteren Autor:innen. Beteiligte Einrichtung: Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Hauptthemen laut MEDLINE: Ovarian Neoplasms, RNA, Long Noncoding, DNA Methylation, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center, National Science Centre in Poland.
Abstract (Originalsprache)
CRNDE is an oncogene expressed as a long non-coding RNA. However, our team previously reported that the CRNDE gene also encodes a micropeptide, CRNDEP. The amino acid sequence of CRNDEP has recently been revealed by other researchers, too. This study aimed to investigate genetic alterations within the CRNDEP-coding region of the CRNDE gene, methylation profiling of this gene, and CRNDEP expression analysis. All investigations were performed on clinical material from patients with ovarian tumors of diverse aggressiveness. We found that CRNDEP levels were significantly elevated in highly aggressive tumors compared to benign neoplasms. Consistently, a high level of this micropeptide was a negative, independent, prognostic, and predictive factor in high-grade ovarian cancer (hgOvCa) patients. The cancer-promoting role of CRNDE(P), shown in our recent study, was also supported by genetic and epigenetic results obtained herein, revealing no CRNDEP-disrupting mutations in any clinical sample. Moreover, in borderline ovarian tumors (BOTS), but not in ovarian cancers, the presence of a single nucleotide polymorphism in CRNDE, rs115515594, significantly increased the risk of recurrence. Consistently, in BOTS only, the same genetic variant was highly overrepresented compared to healthy individuals. We also discovered that hypomethylation of CRNDE is associated with increased aggressiveness of ovarian tumors. Accordingly, hypomethylation of this gene’s promoter/first exon correlated with hgOvCa resistance to chemotherapy, but only in specimens with accumulation of the TP53 tumor suppressor protein. Taken together, these results contribute to a better understanding of the role of CRNDE(P) in tumorigenesis and potentially may lead to improvements in screening, diagnosis, and treatment of ovarian neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Laboratory of Systems Biology, Faculty of Biology, University of Warsaw, 02-106 Warsaw, Poland.
- Laboratory for Microarray Analysis, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland.
- Cancer Molecular and Genetic Diagnostics Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
- Triple Helical Peptides Ltd., Cambridge CB22 5DU, UK.
- Department of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
ORCID-Profile: Laura Aleksandra Szafron, Roksana Iwanicka-Nowicka, Arkadiusz M Bonna, Lukasz Michal Szafron
Förderung
- National Science Center
- National Science Centre in Poland
Zitieren
APA
Szafron, L. A., Iwanicka-Nowicka, R., Podgorska, A., Bonna, A. M., Sobiczewski, P., Kupryjanczyk, J., & Szafron, L. M. (2024). The Clinical Significance of CRNDE Gene Methylation, Polymorphisms, and CRNDEP Micropeptide Expression in Ovarian Tumors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147531
Vancouver
Szafron LA, Iwanicka-Nowicka R, Podgorska A, Bonna AM, Sobiczewski P, Kupryjanczyk J, et al. The Clinical Significance of CRNDE Gene Methylation, Polymorphisms, and CRNDEP Micropeptide Expression in Ovarian Tumors. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147531
BibTeX
@article{Szafron2024,
author = {Szafron, Laura Aleksandra and Iwanicka-Nowicka, Roksana and Podgorska, Agnieszka and Bonna, Arkadiusz M and Sobiczewski, Piotr and Kupryjanczyk, Jolanta and Szafron, Lukasz Michal},
title = {The Clinical Significance of CRNDE Gene Methylation, Polymorphisms, and CRNDEP Micropeptide Expression in Ovarian Tumors},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147531}
}
EUVIMED